DRUG USAGE EVALUATION & INTERVENTION IN AIDS POPULATION

第一阶段的研究将开发和测试一个微型计算机程序 旨在改善活性治疗的药物使用评价（DUE） 艾滋病病毒和机会性病原体。 由于 是一项重要的质量保证活动，但80%到88%的 医院没有有效地将DUE纳入其质量 保证计划。 第一阶段研究将通过以下方式解决这一问题： 开发一个交互式计算机程序， 药剂师访问包含适当DUE的药物数据库 艾滋病病人的管理标准。 该计划将收到 输入患者特征和疾病、药物、治疗和肾脏 功能信息。 基于访问药物的子程序 数据库、药代动力学给药软件和医院的DUE标准 对于艾滋病治疗，该计划的输出将建议修改， 治疗（如需要），并通知医疗保健专业人员 建议或修改的治疗方案的潜在问题。 对该程序的测试将评估该程序的准确性， 建议，使用医院药房的DUE评价， 治疗（P & T）委员会作为“黄金标准”。“最后，由于 新入院的艾滋病患者人群将使用DUE 程序. 方案建议与P建议的一致性 & T委员会将进行评估。

This phase I study would develop and test a microcomputer program intended to improve the drug usage evaluation (DUE) for therapies active against the HIV and opportunistic pathogens in the AIDS population. DUE is an essential quality assurance activity, but 80 to 88% of all hospitals have not effectively incorporated DUE into their quality assurance program. This Phase I study would address this problem through development of an interactive computer program which would allow ready access by the pharmacist to a drug database containing proper DUE criteria for the management of AIDS patients. The program would receive input of patient characteristics and disease, drug, therapeutic and renal function information. Based upon subroutines which access a drug database, pharmacokinetic dosing software and the hospital's DUE criteria for AIDS therapy, the program output would recommend modifications in therapy (if needed) and notifying health care professionals of the potential problems with the proposed or modified therapeutic regimen. Tests of the program would evaluate the accuracy of the program's recommendation, using the DUE evaluation of the hospital pharmacy and therapeutics (P & T) Committee as the "Gold Standard." Finally, DUE of a population of newly admitted AIDS patients would be done using the DUE program. Concurrence of the program's recommendation with that of the P & T Committee would be evaluated.